| Literature DB >> 30686789 |
Oleg Kovrov1, Kristian Kølby Kristensen2,3, Erika Larsson1, Michael Ploug2,3, Gunilla Olivecrona4.
Abstract
Angiopoietin-like (ANGPTL) 8 is a secreted inhibitor of LPL, a key enzyme in plasma triglyceride metabolism. It was previously reported that ANGPTL8 requires another member of the ANGPTL family, ANGPTL3, to act on LPL. ANGPTL3, much like ANGPTL4, is a physiologically relevant regulator of LPL activity, which causes irreversible inactivation of the enzyme. Here, we show that ANGPTL8 can form complexes with either ANGPTL3 or ANGPTL4 when the proteins are refolded together from their denatured states. In contrast to the augmented inhibitory effect of the ANGPTL3/ANGPTL8 complex on LPL activity, the ANGPTL4/ANGPTL8 complex is less active compared with ANGPTL4 alone. In our experiments, all three members of the ANGPTL family use the same mechanism to inactivate LPL, which involves dissociation of active dimeric LPL to monomers. This inactivation can be counteracted by the presence of glycosylphosphatidylinositol-anchored HDL binding protein 1, the endothelial LPL transport protein previously known to protect LPL from spontaneous and ANGPTL4-catalyzed inactivation. Our data demonstrate that ANGPTL8 may function as an important metabolic switch, by forming complexes with ANGPTL3, or with ANGPTL4, in order to direct the flow of energy from triglycerides in blood according to the needs of the body.Entities:
Keywords: angiopoietin-like 3; angiopoietin-like 4; angiopoietin-like 8; enzymology/enzyme regulation; glycosylphosphatidylinositol-anchored HDL binding protein 1; lipoprotein metabolism; triglycerides
Mesh:
Substances:
Year: 2019 PMID: 30686789 PMCID: PMC6446706 DOI: 10.1194/jlr.M088807
Source DB: PubMed Journal: J Lipid Res ISSN: 0022-2275 Impact factor: 5.922